Anthrax Antibody Resubmitted to US FDA by HGS

A week prior to the closing date Human Genome Sciences (HGS) have fixed for prospective buyers to submit bids, HGS have announced that US regulators are to review raxibacumab again for the treatment’s previously-rejected anthrax medication. The US Food and Drug Administration (FDA) have confirmed the receipt of the resubmission of the Biologics License Application

Continue Reading

HGS Bid Extended By GlaxoSmithKline

GlaxoSmithKline (GSK) has prolonged their proposition to acquire Human Genome Sciences (HGS) without increasing their $2.60 billion offer, after barely any shares were offered. The UK drugs giant has delayed the expiration date to June 29th for their unsolicited tender offer to acquire all the remaining common shares of Human Genome Sciences at $13.00 each.

Continue Reading

GlaxoSmithKline Plans to Change Entire HGS Board

GlaxoSmithKline (GSK) wants to change the whole board of Human Genome Sciences (HGS), according to a Reuters report,  and contenders from across the sector have been approached. The news agency, states that GSK will pursue the assistance from Human Genome Sciences shareholders to exchange the board with 12 independent directors.  They claim that the UK

Continue Reading

HGS Adopts Poison Pill to Hinder GSK Bid

Human Genome Sciences (HGS) on Thursday adopted a shareholder rights plan to confront GlaxoSmithKline’s hostile bid, and discharged the GSK’s $2.60 billion proposition as insufficient. A week ago, GlaxoSmithKline (GSK) appealed directly to shareholders, after initially being rejected by HGS last month, with the $13-a-share proposition for GSK’s long-time partner and co-developer of the lupus

Continue Reading

GlaxoSmithKline Submit Hostile HGS Bid Worth $2.60 Billion

GSK’s (GlaxoSmithKline’s) $2.60 billion bid to buy Human Genome Sciences (HGS) has taken a hostile direction, with GSK directly approaching shareholders with their previously-declined offer, instead of participating in HGS’ “strategic alternatives review”. Last month, the board at Human Genome Sciences, which developed Benlysta (belimumab) with GSK, rejected GSK’s $13.00 per share offer, which signified

Continue Reading